Omeros (OMER) Stock Forecast and Price Target (2026)

Last updated November 2026

Short answer

There is no meaningful price-target consensus for Omeros (OMER): too few analysts publish a target on it for an average to mean anything. Thin coverage is normal for smaller and newer companies and says nothing about the business. What does exist is an earnings forecast. For the fiscal year ending Dec 2026, the 3 analysts publishing estimates on OMER expect earnings of $0.69 per share (-67% on the year before) and revenue of $127.5 million (+0.0%). The full quarter and fiscal-year estimates are below, with the drivers and risks that decide whether they are met. Walnut is not an investment adviser.

Why OMER has no consensus price target

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. OMER is one of them. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model.

Screens that show Omeros at roughly 30 times sales are reading a trailing window that mostly predates the product: YARTEMLEA only began selling in January 2026. Against the second-quarter net revenue run rate of about $114 million annualized, the roughly $1.16 billion market value is about ten times sales, and closer to nine times the 2026 consensus of about $128 million, an ordinary multiple for a rare-disease launch and a demanding one if the ramp stalls. The trailing P/E near 13 is not a clean signal either, because trailing net income of about $117 million includes the Novo Nordisk transaction rather than recurring operations.

OMER earnings and revenue forecast

For the fiscal year ending Dec 2026, the 3 analysts publishing estimates on OMER expect earnings of $0.69 per share (-67% on the year before) and revenue of $127.5 million (+0.0%).

PeriodEPS estimateEPS growthRevenue estimateRevenue growth
Quarter ending Sep 2026
next quarter to report, 3 analysts
-$0.02
-$0.05 to $0.01
n/a$37.3 million
$30.9 million to $40.6 million
+0.0%
Quarter ending Dec 2026
the quarter after, 3 analysts
$0.07
-$0.09 to $0.22
-98%$51.8 million
$33.8 million to $72 million
+0.0%
Fiscal year ending Dec 2026
fiscal year next to report, 3 analysts
$0.69
$0.50 to $0.88
-67%$127.5 million
$103.1 million to $151.1 million
+0.0%
Fiscal year ending Dec 2027
the fiscal year after, 3 analysts
$1.23
$0.24 to $2.22
+78%$221.3 million
$191.2 million to $274.3 million
+74%

Consensus estimates for OMER published by sell-side analysts, as of November 2026, from Yahoo Finance. Each figure is the average of the analysts counted, with the lowest and highest estimate beneath it; growth compares with the same period a year earlier and is left blank where either figure is a loss. Estimates change constantly. Walnut is not an investment adviser.

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Omeros next reports around November 12, 2026 (an estimated date), which is when these figures get tested against actual results.

Is there a 2030 forecast for OMER?

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering OMER do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.

The furthest-out consensus that exists is for the fiscal year ending Dec 2027: analysts expect earnings of $1.23 per share, +78% on the fiscal year ending Dec 2026 estimate of $0.69. Beyond that, nobody publishes estimates, so any later number is an extrapolation.

On the figures we hold as of November 2026, OMER trades at about 14.1 times trailing earnings and 14.0 times forward earnings. A forward multiple below the trailing one means the market expects earnings to grow, and the size of that gap is roughly how much growth is already in the price.

For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Omeros can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

What could move OMER from here

In short: the drivers cited most often are The YARTEMLEA launch curve, A repaired balance sheet, not a raised one, The OMIDRIA royalty tail and the Novo milestones. The risk cited most often against it is concentration is the first-order risk: one drug, one indication, one country generating essentially all product revenue, with a patient population measured in the low thousands per year.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the OMER is it a buy page.

Your questions about Omeros

Ask Walnut's AI anything about OMER and see how it fits what you own.

FAQ

What is the price target for Omeros (OMER)?

+

There is no meaningful consensus price target for OMER, because too few analysts publish on it. Thin coverage is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.

Is there an analyst forecast for OMER?

+

For earnings, yes; for the share price, not a meaningful one. For the fiscal year ending Dec 2026, the 3 analysts publishing estimates on OMER expect earnings of $0.69 per share (-67% on the year before) and revenue of $127.5 million (+0.0%). Fewer analysts publish a price target on OMER than publish earnings estimates, which is common for smaller and newer companies, and a lack of target coverage says nothing about the business itself.

What are analysts' earnings estimates for Omeros (OMER)?

+

For the fiscal year ending Dec 2026, the 3 analysts publishing estimates on OMER expect earnings of $0.69 per share (-67% on the year before) and revenue of $127.5 million (+0.0%). For the fiscal year ending Dec 2027, the consensus is $1.23 per share, +78% on the year before. These are consensus estimates as of November 2026, the average of what the covering analysts publish, and they are revised constantly, especially around each earnings report. They describe expectations, not results.

When does OMER report earnings next?

+

Omeros's next earnings report is expected around November 12, 2026, a date estimated from its reporting history that the company has not yet confirmed. The report is when the estimates on this page get tested against actual results, which is why targets and estimates tend to move most in the days after it.

What could move OMER?

+

The drivers and the risks are laid out on this page and in more depth on the OMER "is it a buy" page. Without analyst estimates to anchor to, the useful framing is a set of scenarios.

Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.

Forecasts for similar stocks